A Phase 2 interventional study of active tDCS and active tDCS in Temporomandibular Dysfunction (TMD), sponsored by Federal University of Paraíba. Status unknown at 1 site in Brazil. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-09-18.
Sponsored by Federal University of Paraíba · Phase 2, Interventional, and Treatment
Among 44 studies in Temporomandibular Joint Disorders with a site in Brazil — 7 open to participants now, 7 under way, none of them phase 3. Temporomandibular Joint Disorders · Brazil.
Among the 44 studies in Temporomandibular Joint Disorders with a site in Brazil, this one is the 34th largest by planned enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2017, is one of 2 in phase 2, and was the 32nd registered.
591 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.
Browse Temporomandibular Joint Disorders studies →7 of the 44 studies in Temporomandibular Joint Disorders with a site in Brazil are open now. Recruiting first, the newest first:
Universidade Federal do Rio de Janeiro · Sites in Brazil
Ages 5–16 · Healthy volunteers
University of Sao Paulo General Hospital · Sites in Brazil
Ages 18+ · Healthy volunteers
University of Nove de Julho · Sites in Brazil
Ages 18–60
University of Nove de Julho · Sites in Brazil
Ages 18–60
AO Innovation Translation Center · Sites in Brazil, Colombia, Denmark and 12 more countries
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 75 Temporomandibular Joint Disorders studies recruiting now, 26 (35%) set no upper age limit and 45 (60%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 2
First in 2004; this study’s year is marked. 2 started in 2017.
This study's planned enrollment of 10 is below the median of 45 across 415 interventional studies indexed under Temporomandibular Joint Disorders.
Median enrollment 40 across the 36 interventional studies, 200 across the 7 observational. Of the 27 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 44 has an industry lead sponsor. The 10 most frequent:
Federal University of Paraíba is the lead sponsor of 73 studies on the registry; 6 are open to participants now.
Federal University of Paraíba has 1 study filed under Temporomandibular Joint Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies in Temporomandibular Joint Disorders with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05006963University of Nove de JulhoTele-Rehabilitation in Patients With Temporomandibular Dysfunction | 2026-12-30 |
| NCT05907239University of Sao Paulo General HospitalEffects of Focal Extracorporeal Shock Wave Therapy in the Treatment of Temporomandibular Disorders of Muscular Origin | 2027-11-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies in Temporomandibular Joint Disorders with a site in Brazil, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
active tDCS Participants will receive active transcranial direct current stimulation.
Device: active tDCS
active tDCS Participants will receive active transcranial direct current stimulation.
Device: active tDCS
tDCS Sham Participants will receive sham transcranial direct current stimulation.
Device: sham tDCS
Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left M1 and cathodal over supraorbital contralateral area
Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left DLPFC and cathodal over supraorbital contralateral area.
The procedure is the same as for active tDCS anodal over left M1 and cathodal over supraorbital contralateral area, but the in the placebo tDCS the stimulation is non-active / sham.
Change from baseline in Visual Analogic Scale
The visual analogic scale allows us to convert subjective sensations as pain on numerical data. A 10cm scale where 0cm is no pain and 10cm the worse imaginable pain, will be used and the subjects will be asked to mark a point on the scale representing their pain. This instrument will be used to compare the VAS values before and after the intervention.
Time frame: 4 months
Patient Global Impression of Change Scale (PGICS)
The Patient Global Impression of Change Scale (PGICS) is an understandable, adequate, easy-to-use instrument capable of measuring the perception of change in health status and satisfaction with the treatment of individuals with chronic musculoskeletal pain. It is a one-dimensional measurement instrument in which individuals rate their improvement associated with intervention on a 7-item scale ranging from 1 (no change) to 7 (Much better).
Time frame: 4 months
State-Trait Anxiety Inventory
The STAI is used to evaluate objectively both aspects of anxiety: trait and state. Thus, the anxiety state will assess the level of anxiety at the specific time the test is performed and the anxiety trait will investigate the individual's willingness to react to stress situations. It is an instrument with 40 descriptive statements about the feelings of the person, distributed in two parts (trace and state of anxiety), in which each part is formed by 20 affirmations and the answers are given in scale of the type Likert of four points (1 - absolutely not the 4 - very much). The score in each questionnaire ranges from 20 to 80, with an anxiety level rating of: low (20 to 33), mean (33 to 49) and high (49 to 80).
Time frame: 4 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2017; primary completion for Jan 2018, 3 months later.
Of 14 phase 2 interventional studies under Temporomandibular Joint Disorders, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 39. This study's planned 3 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Temporomandibular Joint Disorders →
Federal University of Paraíba